论文部分内容阅读
作为细菌感染症的化学疗法,口服抗药物中成为主流的吡啶酮羧酸(PCA)类药物由1962年的萘啶酸(NA)开始,迄今已开发了大量药剂。PCA 类抗菌药物大致可分为旧PCA 类和新 PCA 类(即所谓新喹诺酮类)。以NA 为代表的旧 PCA 类药物只对革兰氏阴性菌表现抗菌活性,其临床适应症仅限于尿路感染、肠道感染、胆道感染等少数疾病。但以氟哌酸(NFLX)为代表的新喹诺酮类药物与旧 PCA 类比较,抗菌谱除革兰氏阴性杆菌
As a chemotherapy for bacterial infections, the main source of pyridone carboxylic acid (PCA) in oral antidrugs started with nalidixic acid (NA) in 1962 and a large number of agents have been developed so far. PCA class antibacterial drugs can be broadly divided into the old PCA class and the new PCA class (the so-called new quinolones). The old PCAs, represented by NA, showed antibacterial activity only against Gram-negative bacteria. The clinical indications were limited to a few diseases such as urinary tract infections, intestinal infections and biliary tract infections. However, the new fluoroquinolones (NFLX) represented quinolone drugs compared with the old PCA class, antimicrobial spectrum in addition to Gram-negative bacilli